Muc1
Clinical Trials Overview
1 trials found
About Muc1
MUC1 is a mucin glycoprotein that is overexpressed on the surface of many cancer cells, including colorectal tumors. MUC1-targeted therapies utilize immunotherapeutic approaches to generate immune responses against cancer cells displaying this antigen.
Category
Other Medications
Brand Name
Various
Mechanism
These treatments work by training the immune system to recognize and attack cells expressing the MUC1 protein through vaccine-based approaches or adoptive cell transfer methods. The immune response targets the aberrantly expressed MUC1 on tumor cells while sparing normal tissues.
1
Total Trials
1
Recruiting
0
Active
0
Completed
40
Total Enrollment
1
Countries
med_trials_active_sites
Recruiting sites
1 countries
NCT04842812
Phase 1
Recruiting
40 patients
Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs against various antigens, followed by transfusion into the patients. T...
China